Application of Ion-Exchange Resin Column for Basic Development of Strontium-90/Yttrium-90 Generator for Preparation of Radiopharmaceutical Therapy

Muchtaridi Muchtaridi(1), Elvan Kamal(2), Anas Subarnas(3), Abdul Mutalib(4*)

(1) Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Jatinangor KM 21-Sumedang 45363, West Java
(2) Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Jatinangor KM 21-Sumedang 45363, West Java
(3) Department of Pharmacology, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Jatinangor KM 21-Sumedang 45363, West Java
(4) Department of Chemistry, Faculty of Mathematic and Natural Sciences, Universitas Padjadjaran, Jl. Jatinangor KM 21-Sumedang 45363, West Java
(*) Corresponding Author


The aim of this study is to examine the possible use of ion-exchange resin on Dowex AG 50x8 in separating Y-90 from Sr-90 which then could be applied in the basic of manufacture of producing Sr-90/Y-90 generator for the production of radiopharmaceutical cancer therapy. The findings showed that a distributive coefficient of Sr-90 and Y-90 with HCl 6 N solvent showed that distributive coefficient of Sr-90 in cation-exchange resin on Dowex 50x8 was greater than Y-90. Y-90 in HCl 6 N solvent was more easily eluted, while Sr-90 was bound to resin.. In conclusion, resin on Dowex AG 50x8 with HCl 6 N elution solvent might be able to separate Y-90 from Sr-90 as the basis for Sr-90/Y-90 generator.


Generator; Strontium-90; Yttrium-90; ion-exchange resin

Full Text:

Full Text Pdf


[1] Muchtaridi, M., Yusuf, M., Diantini, A., Choi, S., Al-Najjar, B., Manurung, J., Subarnas, A., Achmad, T., Wardhani, S., and Wahab, H., 2014, Potential activity of fevicordin-A from Phaleria macrocarpa (Scheff) Boerl. seeds as estrogen receptor antagonist based on cytotoxicity and molecular modelling studies, Int. J. Mol. Sci., 15 (5), 7225–7249.

[2] Fink-Bennett, D.M., and Thomas, K., 2003, 90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma, J. Nucl. Med. Technol., 31, 61–68.

[3] Chakravarty R., Dash, A., and Pillai, M.R., 2012, Availability of yttrium-90 from strontium-90: A nuclear medicine perspective, Cancer Biother. Radiopharm., 27 (10), 621–641.

[4] Montaña, R.L., González, I.H., Ramirez, A.A., Garaboldi, L., and Chinol, M., 2012, Yttrium-90–current status, expected availability and applications of a high beta energy emitter, Curr. Radiopharm., 5 (3), 253–263.

[5] Venkatesh, M., Usha, C., and Pillai, M., 2015, 90Y and 105Rh labeled preparations: potential therapeutic agents, Proceeding of International seminar on therapeutic applications of radiopharmaceuticals, Hyderabad, India 18-22 Jan 1999.

[6] Raval, M., Bande, D., Pillai, A.K., Blaszkowsky, L.S., Ganguli, S., Beg, M.S., and Kalva, S.P., 2014, Yttrium-90 radioembolization of hepatic metastases from colorectal cancer, Front. Oncol., 4, 1–8.

[7] Khajornjiraphan, N., Thu, N.A., and Chow, P.K., 2015, Yttrium-90 microspheres: A review of its emerging clinical indications, Liver Cancer, 4, 6–15.

[8] Zalutsky, M.R., 2000, “Radiohalogens for Radioimmunotherapy” in Radioimmunotherapy of Cancer, ed. Abrams, P.G., and Fritzberg, A.R., CRC Press, 61–86.

[9] Wang, M., Oki, Y., Pro, B., Romaguera, J.E., Rodriguez, M.A. Samaniego, F., McLaughlin, P., Hagemeister, F., Neelapu, S., Copeland, A., Samuels, B.I., Loyer, E.M., Ji, Y., and Younes, A., 2009, Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma, J. Clin. Oncol., 27 (31), 5213–5218.

[10] Bowen, B.M., Darracott, J., Garnett, E.S., and Tomlinson, R.H., 1975, Yttrium-90 citrate colloid for radioisotope synovectomy, Am. J. Hosp. Pharm., 32 (10), 1027–1030.

[11] Zade, A.A., Rangarajan, V., Purandare, N.C., Shah, S.A., Agrawal, A.R., Kulkarni, S.S., and Shetty, N., 2013, 90Y microsphere therapy: does 90Y PET/CT imaging obviate the need for 90Y Bremsstrahlung SPECT/CT imaging?, Nucl. Med. Commun., 34 (11), 1090–1096.

[12] Virgolini, I., Britton, K., Buscombe, J., Moncayo, R., Paganelli, G., and Riva, P., 2002, In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial, Semin. Nucl. Med., 32 (2), 148–155.

[13] Esteban, J.M., Hyams, D.M., Beatty, B.G., Wanek, P., and Beatty, J.D., 1989, Effect of yttrium-90-labeled anti-carcinoembryonic antigen monoclonal antibody on the morphology and phenotype of human tumors grown as peritoneal carcinomatosis in athymic mice, Cancer, 63 (7), 1343–1352.

[14] Ingargiola, M., Runge, R., Heldt, J.M., Freudenberg, R., Steinbach, J., Cordes, N., Baumann, M., Kotzerke, J., Brockhoff, G., and Kunz-Schughart, L.A., 2014, Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay, Int. J. Cancer, 135 (4), 968–980.

[15] Talmage, S., Formal Toxicity Summary for STRONTIUM-90, strontium_90_f_V1.html, accessed on 26 december 2014.

[16] Driver, C.J., 1994, Ecotoxicity literature review of selected Hanford Site contaminants, Pacific Northwest Laboratory for United States Department of Energy, Richland, WA-United States, 134.

[17] Sahoo, S.K., Kavasi, N., Sorimachi, A., Arae, H., Tokonami, S., Mietelski, J.W., Lokas, E., and Yoshida, S., 2016, Strontium-90 activity concentration in soil samples from the exclusion zone of the Fukushima daiichi nuclear power plant, Sci. Rep., 6, 23925.

[18] International Atomic Energy Agency (IAEA), 2009, Therapeutic Radionuclide Generators: 90Sr/90Y and 188W/188Re Generators, Technical reports series 470, Viena, Austria.

[19] Mikolajczak, R., Zuchlinska, M., Korsak, A., Iller, E., Pawlak, D., Zelek, Z., Konior, M., and Parus, J.L., 2009, “Determination of 90Sr in the 90Y Eluates of the 90Sr/90Y Generator” In Therapeutic Radionuclide Generators: 90Sr/90Y and 188W/188Re Generators, IAEA, Ed. Viena, Austria, 470, 101–105.

[20] MacMillan, J.P., Park, J.W., Gerstenberg, R., Wagner, H., Köhler, K., and Wallbrecht, P., 2000, “Strontium and Strontium Compounds” In Ullmann's Encyclopedia of Industrial Chemistry, Wiley-VCH Verlag GmbH & Co. KGaA.

[21] Carballa, M., Fink, G., Omil, F., Lema, J.M., and Ternes, T., 2008, Determination of the solid–water distribution coefficient (Kd) for pharmaceuticals, estrogens and musk fragrances in digested sludge, Water Res., 42 (1-2), 287–295.

[22] Meloan, C.E., 1999, Chemical Separations: Principles, Techniques and Experiments, John Wiley & Sons, Inc.

[23] Venkatesh, M., Dash, A., Pandey, U., Dhami, P.S., and Chakravarty, R., 2009, “Development of Sr/Y Generator Technologies and Their Evaluation for Use in the Preparation Radiopharmaceuticals” in Therapeutic Radionuclide Generators: 90Sr/90Y and 188W/188Re Generators, IAEA, Ed. Viena, Austria, 470, 73-82.

[24] L'Annunziata, M.F., 2012, Handbook of Radioactivity Analysis, Elsevier Science.

[25] Rusdiarso, B., 2007, Synergistic extraction of Cobalt(II) with mixture of acyl-pyrazolon and crown-ether in Stronsium(II) environment, Indones. J. Chem., 7 (1), 43-48.

[26] Castillo, A.X., Berdeguez, M.T., Beckford, D., Leyva Montaña, R., Casanova González, E., and Moreno, Y., 2009, “Development of a Reproducible Methodology for the Production of 90Y from a 90Sr/90Y Chromatographic Generator” in Therapeutic Radionuclide Generators: 90Sr/90Y and 188W/188Re Generators, IAEA, Ed. Viena, Austria, 470, 57–71.


Article Metrics

Abstract views : 861 | views : 1959

Copyright (c) 2017 Indonesian Journal of Chemistry

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.


Indonesian Journal of Chemisty (ISSN 1411-9420 / 2460-1578) - Chemistry Department, Universitas Gadjah Mada, Indonesia.

Analytics View The Statistics of Indones. J. Chem.